The molecular mechanism of METTL3 promoting the malignant progression of lung cancer

Cancer Cell Int. 2022 Mar 24;22(1):133. doi: 10.1186/s12935-022-02539-5.

Abstract

Lung cancer remains one of the major causes of cancer-related death globally. Recent studies have shown that aberrant m6A levels caused by METTL3 are involved in the malignant progression of various tumors, including lung cancer. The m6A modification, the most abundant RNA chemical modification, regulates RNA stabilization, splicing, translation, decay, and nuclear export. The methyltransferase complex plays a key role in the occurrence and development of many tumors by installing m6A modification. In this complex, METTL3 is the first identified methyltransferase, which is also the major catalytic enzyme. Recent findings have revealed that METTL3 is remarkably associated with different aspects of lung cancer progression, influencing the prognosis of patients. In this review, we will focus on the underlying mechanism of METT3 in lung cancer and predict the future work and potential clinical application of targeting METTL3 for lung cancer therapy.

Keywords: Inhibitors; Lung cancer; METTL3; Malignant progression; Prognosis; Tumor microenvironment; m6A.

Publication types

  • Review